{{PBB|geneid=50652}}

'''Prostate cancer antigen 3''' ('''PCA3''', also referred to as '''DD3''') is a gene that expresses a [[non-coding RNA]]. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in [[prostate cancer]].<ref name="pmid10606244">{{cite journal |author=Bussemakers MJ, van Bokhoven A, Verhaegh GW, ''et al.'' |title=DD3: a new prostate-specific gene, highly overexpressed in prostate cancer |journal=Cancer Res. |volume=59 |issue=23 |pages=5975–9 |year=1999 |month=December |pmid=10606244 |doi= |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=10606244}}</ref><ref name="pmid18640109">{{cite journal |author=Neves AF, Araújo TG, Biase WK, ''et al.'' |title=Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis |journal=Clin. Biochem. |volume= 41|issue= 14-15|pages= 1191|year=2008 |month=July |pmid=18640109 |doi=10.1016/j.clinbiochem.2008.06.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(08)00245-2}}</ref> Because of its restricted expression profile, the PCA3 RNA is useful as a [[tumor marker]].<ref name="pmid18684556">{{cite journal |author=Loeb S |title=Does PCA3 Help Identify Clinically Significant Prostate Cancer? |journal=Eur. Urol. |volume= 54|issue= 5|pages= 980|year=2008 |month=July |pmid=18684556 |doi=10.1016/j.eururo.2008.07.027 |url=http://linkinghub.elsevier.com/retrieve/pii/S0302-2838(08)00853-1}}</ref>

==Use as biomarker==
The most frequently used [[biomarker]] for prostate cancer today is the [[blood serum|serum]] level of [[prostate-specific antigen]] (PSA), or derived measurements. However, since PSA is [[prostate]]-specific but not [[cancer]]-specific, it is an imperfect biomarker. For example, PSA can increase in older men with [[benign prostatic hyperplasia]]. Several new biomarkers are being investigated to improve the diagnosis of prostate cancer. Some of these can be measured in [[urine sample]]s, and it is possible that a combination of several urinary biomarkers will replace PSA in the future.<ref name="pmid18245462">{{cite journal |author=Laxman B, Morris DS, Yu J, ''et al.'' |title=A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer |journal=Cancer Res. |volume=68 |issue=3 |pages=645–9 |year=2008 |month=February |pmid=18245462 |pmc=2998181 |doi=10.1158/0008-5472.CAN-07-3224 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18245462}}</ref>

Compared to serum PSA, PCA3 has a lower [[Sensitivity and  specificity#Sensitivity|sensitivity]] but a higher [[Sensitivity and  specificity#Specificity|specificity]] and a better [[positive predictive value|positive]] and [[negative predictive value]].<ref name="pmid18538269">{{cite journal |author=Vlaeminck-Guillem V, Ruffion A, Andre J |title=[Value of urinary PCA3 test for prostate cancer diagnosis] |language=French |journal=Prog. Urol. |volume=18 |issue=5 |pages=259–65 |year=2008 |month=May |pmid=18538269 |doi=10.1016/j.purol.2008.03.029 |url=http://linkinghub.elsevier.com/retrieve/pii/S1166-7087(08)00129-2}}</ref> It is independent of prostate volume, whereas PSA is not.<ref name="pmid18295257">{{cite journal |author=Deras IL, Aubin SM, Blase A, ''et al.'' |title=PCA3: a molecular urine assay for predicting prostate biopsy outcome |journal=J. Urol. |volume=179 |issue=4 |pages=1587–92 |year=2008 |month=April |pmid=18295257 |doi=10.1016/j.juro.2007.11.038 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(07)03077-7}}</ref> It should be measured in the first portion of urine after [[prostate massage]] with [[digital rectal examination]].<ref name="pmid18602209"/>

PCA3 has been shown to be useful to predict the presence of malignancy in men undergoing repeat [[prostate biopsy]].<ref name="pmid18602209">{{cite journal |author=Haese A, de la Taille A, van Poppel H, ''et al.'' |title=Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy |journal=Eur. Urol. |volume= 54|issue= 5|pages= 1081|year=2008 |month=June |pmid=18602209 |doi=10.1016/j.eururo.2008.06.071 |url=http://linkinghub.elsevier.com/retrieve/pii/S0302-2838(08)00778-1}}</ref><ref name="pmid17382159">{{cite journal |author=Marks LS, Fradet Y, Deras IL, ''et al.'' |title=PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy |journal=Urology |volume=69 |issue=3 |pages=532–5 |year=2007 |month=March |pmid=17382159 |doi=10.1016/j.urology.2006.12.014 |url=http://linkinghub.elsevier.com/retrieve/pii/S0090-4295(06)02638-0}}</ref> This means that it could be useful clinically for a patient for whom digital rectal examination and PSA suggest possible prostate cancer, but the first prostate biopsy returns a normal result. This occurs in approximately 60% of cases, and on repeat testing, 20-40% have an abnormal biopsy result.<ref name="pmid17892357">{{cite journal |author=de la Taille A |title=Progensa PCA3 test for prostate cancer detection |journal=Expert Rev. Mol. Diagn. |volume=7 |issue=5 |pages=491–7 |year=2007 |month=September |pmid=17892357 |doi=10.1586/14737159.7.5.491 |url=http://www.future-drugs.com/doi/abs/10.1586/14737159.7.5.491?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov}}</ref>

Other uses that are being studied for PCA3 include its correlation with adverse tumor features such as tumor volume, [[tumor grading|grading]] ([[Gleason score]]) or extracapsular extension. These studies have so far produced conflicting results.<ref name="pmid18353398">{{cite journal |author=Nakanishi H, Groskopf J, Fritsche HA, ''et al.'' |title=PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance |journal=J. Urol. |volume=179 |issue=5 |pages=1804–9; discussion 1809–10 |year=2008 |month=May |pmid=18353398 |doi=10.1016/j.juro.2008.01.013 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(08)00016-5}}</ref><ref name="pmid18500693">{{cite journal |author=van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, ''et al.'' |title=Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results |journal=Prostate |volume=68 |issue=11 |pages=1215–22 |year=2008 |month=August |pmid=18500693 |doi=10.1002/pros.20781}}</ref><ref name="pmid18801539">{{cite journal |author=Whitman EJ, Groskopf J, Ali A, ''et al.'' |title=PCA3 Score Before Radical Prostatectomy Predicts Extracapsular Extension and Tumor Volume |journal=J. Urol. |volume= 180|issue= 5|pages= 1975|year=2008 |month=September |pmid=18801539 |doi=10.1016/j.juro.2008.07.060 |url=http://linkinghub.elsevier.com/retrieve/pii/S0022-5347(08)01863-6}}</ref>

A commercial kit called the Progensa PCA3 test is marketed by the Californian company [[Gen-Probe]]. PCA3 Rights acquired from [[Diagnocure]] back in 2003. Royalties of 16% of cumulative sales of PCA3 kit are paid to Diagnocure. Diagnocure is quoted on TSX
as CUR.TO (Canada) <ref name="pmid17892357"/> 
<ref>[http://www.progensapca3.net/ Progensa PCA3 test] - Gen-probe. Retrieved October 1, 2008.</ref>

==Discovery==
PCA3 was discovered to be highly expressed by prostate cancer cells in 1999.<ref name="pmid10606244"/>

==References==
{{reflist|2}}

==Further reading==
{{refbegin | 2}}
*{{cite journal  |author=Clarke RA, Zhao Z, Guo AY, ''et al.''  |editor1-last=Zhang  |editor1-first=Baohong |title=New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. |journal=PLoS ONE |volume=4 |issue= 3 |pages= e4995 |year= 2009 |pmid= 19319183  |pmc=2655648 |doi= 10.1371/journal.pone.0004995 }}
*{{cite journal  |author=Schilling D, Hennenlotter J, Munz M, ''et al.'' |title=Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. |journal=Urol. Int. |volume=85 |issue= 2 |pages= 159–65 |year= 2010 |pmid= 20424427 |doi= 10.1159/000314078 }}
*{{cite journal  |author=Day JR, Jost M, Reynolds MA, ''et al.'' |title=PCA3: from basic molecular science to the clinical lab. |journal=Cancer Lett. |volume=301 |issue= 1 |pages= 1–6 |year= 2011 |pmid= 21093148 |doi= 10.1016/j.canlet.2010.10.019 }}
*{{cite journal  |author=Schalken JA, Hessels D, Verhaegh G |title=New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. |journal=Urology |volume=62 |issue= 5 Suppl 1 |pages= 34–43 |year= 2003 |pmid= 14607216 |doi=10.1016/S0090-4295(03)00759-3  }}
*{{cite journal  |author=Ankerst DP, Groskopf J, Day JR, ''et al.'' |title=Predicting prostate cancer risk through incorporation of prostate cancer gene 3. |journal=J. Urol. |volume=180 |issue= 4 |pages= 1303–8; discussion 1308 |year= 2008 |pmid= 18707724 |doi= 10.1016/j.juro.2008.06.038 }}
*{{cite journal  |author=Roobol MJ, SchrÃ¶der FH, van Leeuwen P, ''et al.'' |title=Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. |journal=Eur. Urol. |volume=58 |issue= 4 |pages= 475–81 |year= 2010 |pmid= 20637539 |doi= 10.1016/j.eururo.2010.06.039 }}
*{{cite journal  |author=Sokoll LJ, Ellis W, Lange P, ''et al.'' |title=A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. |journal=Clin. Chim. Acta |volume=389 |issue= 1-2 |pages= 1–6 |year= 2008 |pmid= 18061575 |doi= 10.1016/j.cca.2007.11.003 }}
*{{cite journal  |author=Hessels D, Schalken JA |title=The use of PCA3 in the diagnosis of prostate cancer. |journal=Nat Rev Urol |volume=6 |issue= 5 |pages= 255–61 |year= 2009 |pmid= 19424173 |doi= 10.1038/nrurol.2009.40 }}
*{{cite journal  |author=Salagierski M, Verhaegh GW, Jannink SA, ''et al.'' |title=Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. |journal=Prostate |volume=70 |issue= 1 |pages= 70–8 |year= 2010 |pmid= 19760627 |doi= 10.1002/pros.21040 }}
*{{cite journal  |author=Haese A, de la Taille A, van Poppel H, ''et al.'' |title=Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. |journal=Eur. Urol. |volume=54 |issue= 5 |pages= 1081–8 |year= 2008 |pmid= 18602209 |doi= 10.1016/j.eururo.2008.06.071 }}
*{{cite journal  |author=Gandini O, Luci L, Stigliano A, ''et al.'' |title=Is DD3 a new prostate-specific gene? |journal=Anticancer Res. |volume=23 |issue= 1A |pages= 305–8 |year=  2003|pmid= 12680228 |doi=  }}
*{{cite journal  |author=Hessels D, van Gils MP, van Hooij O, ''et al.'' |title=Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. |journal=Prostate |volume=70 |issue= 1 |pages= 10–6 |year= 2010 |pmid= 19708043 |doi= 10.1002/pros.21032 }}
*{{cite journal  |author=Klecka J, Holubec L, Pesta M, ''et al.'' |title=Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. |journal=Anticancer Res. |volume=30 |issue= 2 |pages= 665–70 |year= 2010 |pmid= 20332487 |doi=  }}
*{{cite journal  |author=Thelen P, Burfeind P, Grzmil M, ''et al.'' |title=cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non-neoplastic prostate tissue separated by laser microdissections. |journal=Int. J. Oncol. |volume=24 |issue= 5 |pages= 1085–92 |year= 2004 |pmid= 15067329 |doi=  }}
*{{cite journal  |author=Tao Z, Shen M, Zheng Y, ''et al.'' |title=PCA3 gene expression in prostate cancer tissue in a Chinese population: quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. |journal=Exp. Mol. Pathol. |volume=89 |issue= 1 |pages= 58–62 |year= 2010 |pmid= 20114043 |doi= 10.1016/j.yexmp.2010.01.008 }}
*{{cite journal  |author=Hessels D, Klein Gunnewiek JM, van Oort I, ''et al.'' |title=DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. |journal=Eur. Urol. |volume=44 |issue= 1 |pages= 8–15; discussion 15–6 |year= 2003 |pmid= 12814669 |doi=10.1016/S0302-2838(03)00201-X  }}
*{{cite journal  |author=Mearini E, Antognelli C, Del Buono C, ''et al.'' |title=The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. |journal=Biomarkers |volume=14 |issue= 4 |pages= 235–43 |year= 2009 |pmid= 19489685 |doi= 10.1080/13547500902807306 }}
{{refend}}

==External links==
* {{MeshName|prostate+cancer+antigen+3,+human}}

{{Tumor markers}}

[[Category:Non-coding RNA]]
[[Category:RNA]]
[[Category:Tumor markers]]